Therapeutics
Actinium-225 and astatine-211. The same know-how and expertise behind both.
Ionetix supplies alpha emitters to drug developers from one purpose-built facility in Lansing, Michigan, with production, radiochemistry, and quality under one roof.
Isotope access and supply redundancy are core constraints for researchers and drug developers running targeted alpha therapy (TAT) programs.
Ionetix produces two leading alpha emitters, actinium-225 (Ac-225) and astatine-211 (At-211), at a single purpose-built facility in Lansing, Michigan. Production process know-how, radiochemistry, quality and distribution sit together in one building.
Actinium-225 has been supplied as actinium nitrate or actinium chloride to drug developers in North America, Europe and Asia since 2024, and can be distributed globally.
Astatine-211 is supplied as an irradiated solid target or in solvent of choice. Commercial shipments across North America began in September 2026.
Shipping
- Half-life
- ~9.9 days
- Decay
- α
- Production
- Cyclotron
Ac-225
Produced from a radium-226 route, with no detectable actinium-227 co-produced. Supplied to programs in North America, Europe and Asia since 2024.
Shipping
- Half-life
- ~7.2 hr
- Decay
- α
- Production
- Cyclotron
At-211
A 7.2-hour half-life, supplied in solid or solution form. First North American commercial supply since September 2026.
FAQ
Ionetix supplies actinium-225 (Ac-225) and astatine-211 (At-211) to researchers and drug developers running targeted alpha therapy programs. Both are produced at a single purpose-built facility in Lansing, Michigan, USA.
Actinium-225 is supplied as actinium nitrate or actinium chloride. Astatine-211 is supplied as an irradiated solid target or in the customer's solvent of choice.
Actinium-225 has been supplied to drug developers in North America, Europe and Asia since 2024. Astatine-211 ships across North America.
Contact